Search Results - "GALINSKY, I"

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells by Etchin, J, Berezovskaya, A, Conway, A S, Galinsky, I A, Stone, R M, Baloglu, E, Senapedis, W, Landesman, Y, Kauffman, M, Shacham, S, Wang, J C Y, Look, A T

“…Acute myeloid leukemia (AML) is a clonal hematologic malignant disease of developing myeloid cells that have acquired aberrant survival, uncontrolled…”
Get full text

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia by DeAngelo, D J, Stevenson, K E, Dahlberg, S E, Silverman, L B, Couban, S, Supko, J G, Amrein, P C, Ballen, K K, Seftel, M D, Turner, A R, Leber, B, Howson-Jan, K, Kelly, K, Cohen, S, Matthews, J H, Savoie, L, Wadleigh, M, Sirulnik, L A, Galinsky, I, Neuberg, D S, Sallan, S E, Stone, R M

“…On the basis of the data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on…”
Get full text

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice by Etchin, J, Montero, J, Berezovskaya, A, Le, B T, Kentsis, A, Christie, A L, Conway, A S, Chen, W C, Reed, C, Mansour, M R, Ng, C E L, Adamia, S, Rodig, S J, Galinsky, I A, Stone, R M, Klebanov, B, Landesman, Y, Kauffman, M, Shacham, S, Kung, A L, Wang, J C Y, Letai, A, Look, A T

“…Currently available combination chemotherapy for acute myeloid leukemia (AML) often fails to result in long-term remissions, emphasizing the need for novel…”
Get full text

Smac mimetics: implications for enhancement of targeted therapies in leukemia by Weisberg, E, Ray, A, Barrett, R, Nelson, E, Christie, A L, Porter, D, Straub, C, Zawel, L, Daley, J F, Lazo-Kallanian, S, Stone, R, Galinsky, I, Frank, D, Kung, A L, Griffin, J D

“…Drug resistance is a growing concern with clinical use of tyrosine kinase inhibitors. Utilizing in vitro models of intrinsic drug resistance and…”
Get full text

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells by Bhanot, H, Reddy, M M, Nonami, A, Weisberg, E L, Bonal, D, Kirschmeier, P T, Salgia, S, Podar, K, Galinsky, I, Chowdary, T K, Neuberg, D, Tonon, G, Stone, R M, Asara, J, Griffin, J D, Sattler, M

“…The rapid proliferation of myeloid leukemia cells is highly dependent on increased glucose metabolism. Through an unbiased metabolomics analysis of leukemia…”
Get full text

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors by Weisberg, E, Liu, Q, Nelson, Erik, Kung, A L, Christie, A L, Bronson, R, Sattler, M, Sanda, T, Zhao, Z, Hur, W, Mitsiades, C, Smith, R, Daley, J F, Stone, R, Galinsky, I, Griffin, J D, Gray, N

“…Acute myeloid leukemia (AML) progenitors are frequently characterized by activating mutations in the receptor tyrosine kinase Fms-like tyrosine kinase-3…”
Get full text

Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML by Wu, H, Wang, A, Qi, Z, Li, X, Chen, C, Yu, K, Zou, F, Hu, C, Wang, W, Zhao, Z, Wu, J, Liu, J, Liu, X, Wang, L, Zhang, S, Stone, R M, Galinsky, I A, Griffin, J D, Weinstock, D, Christodoulou, A, Wang, H, Shen, Y, Zhai, Z, Weisberg, E L, Liu, J, Liu, Q

Get full text

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome by SEKERES, M. A, STONE, R. M, ZAHRIEH, D, NEUBERG, D, MORRISON, V, DE ANGELO, D. J, GALINSKY, I, LEE, S. J

“…Older patients with acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (aMDS) must decide between receiving intensive induction chemotherapy…”
Get full text

Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias by PALOMERO, T, MCKENNA, K, ASTER, J. C, LOOK, A. T, FERRANDO, A. A, O-NEIL, J, GALINSKY, I, STONE, R, SUZUKAWA, K, STIAKAKI, E, KALMANTI, M, FOX, E. A, CALIGIURI, M. A

“…Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1…”
Get full text

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) by LEVINE, R. L, WADLEIGH, M, STERNBERG, D. W, WLODARSKA, I, GALINSKY, I, STONE, R. M, DEANGELO, D. J, GILLILAND, D. Gary, COOLS, J

“…We report the cloning of a novel PDGFRB fusion gene partner in a patient with a chronic myeloproliferative disorder characterized by t(5;14)(q33;q32), who…”
Get full text

Smac mimetics: implications for enhancement of targeted therapies in leukemia by Weisberg, E, Ray, A, Barrett, R, Nelson, E, Christie, A L, Porter, D, Straub, C, Zawel, L, Daley, J F, Lazo-kallanian, S, Stone, R, Galinsky, I, Frank, D, Kung, A L, Griffin, J D

Get full text

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY by Reiter, A., Gotlib, J., Álvarez‐Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie‐Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J.

Get full text

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE by Reiter, A., Gotlib, J., Álvarez‐Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie‐Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J.

Get full text

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY by Reiter, A., Gotlib, J., Álvarez‐Twose, I., Radia, D. H., Luebke, J., Bobbili, P. J., Wang, A., Norregaard, C., Dimitrijević, S., Sullivan, E., Louie‐Gao, M., Schwaab, J., Galinsky, I. A., Perkins, C., Sperr, W. R., Sriskandarajah, P., Chin, A., Sendhil, S. R., Duh, M. S., Valent, P., DeAngelo, D. J.

Get full text

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial by Stone, R M, De Angelo, J, Galinsky, I, Estey, E, Klimek, V, Grandin, W, Lebwohl, D, Yap, A, Cohen, P, Fox, E, Neuberg, D, Clark, J, Gilliland, D G, Griffin, J D

Get full text

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome by Cools, Jan, DeAngelo, Daniel J, Gotlib, Jason, Stover, Elizabeth H, Legare, Robert D, Cortes, Jorges, Kutok, Jeffrey, Clark, Jennifer, Galinsky, Ilene, Griffin, James D, Cross, Nicholas C.P, Tefferi, Ayalew, Malone, James, Alam, Rafeul, Schrier, Stanley L, Schmid, Janet, Rose, Michal, Vandenberghe, Peter, Verhoef, Gregor, Boogaerts, Marc, Wlodarska, Iwona, Kantarjian, Hagop, Marynen, Peter, Coutre, Steven E, Stone, Richard, Gilliland, D. Gary

“…A fusion between the PDGFRA and FIP1L1 genes was found in some cases of the hypereosinophilic syndrome, a fatal disorder in which eosinophils invade and…”
Get full text

Muc1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy by Rosenblatt, J, Stroopinsky, D, Mills, H, Luptakova, K, Vasir, B, Joyce, R.M, Levine, J.D, Tzachanis, D, Arnason, J, Galinsky, I, Stone, R, Kufe, D, Reiter, Y, Avigan, D.E

Get full text

Proteomic and Genetic Approaches Identify Syk as an AML Target by Hahn, Cynthia K., Berchuck, Jacob E., Ross, Kenneth N., Kakoza, Rose M., Clauser, Karl, Schinzel, Anna C., Ross, Linda, Galinsky, Ilene, Davis, Tina N., Silver, Serena J., Root, David E., Stone, Richard M., DeAngelo, Daniel J., Carroll, Martin, Hahn, William C., Carr, Steven A., Golub, Todd R., Kung, Andrew L., Stegmaier, Kimberly

“…Cell-based screening can facilitate the rapid identification of compounds inducing complex cellular phenotypes. Advancing a compound toward the clinic,…”
Get full text

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia by Wu, H, Hu, C, Wang, A, Weisberg, E L, Chen, Y, Yun, C-H, Wang, W, Liu, Y, Liu, X, Tian, B, Wang, J, Zhao, Z, Liang, Y, Li, B, Wang, L, Wang, B, Chen, C, Buhrlage, S J, Qi, Z, Zou, F, Nonami, A, Li, Y, Fernandes, S M, Adamia, S, Stone, R M, Galinsky, I A, Wang, X, Yang, G, Griffin, J D, Brown, J R, Eck, M J, Liu, J, Gray, N S, Liu, Q

“…Bruton’s tyrosine kinase (BTK) kinase is a member of the TEC kinase family and is a key regulator of the B-cell receptor (BCR)-mediated signaling pathway. It…”
Get full text

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission by Rosenblatt, J, Stone, R, Avivi, I, Uhl, L, Neuberg, D, Joyce, R.M, Tzachanis, D, Levine, J.D, Boussiotis, V, Zwicker, J, Arnason, J, Luptakova, K, Steesma, D, DeAngelo, D, Galinsky, I, Vasir, B, Somaiya, P, Mills, H, Yuan, E, Bonhoff, J, Delaney, C, Drummy, N, Nicholson, L, Stroopinsky, D, Held, V, Katz, T, Rowe, J, Kufe, D, Avigan, D.E

Get full text